JP2014159478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014159478A5 JP2014159478A5 JP2014111127A JP2014111127A JP2014159478A5 JP 2014159478 A5 JP2014159478 A5 JP 2014159478A5 JP 2014111127 A JP2014111127 A JP 2014111127A JP 2014111127 A JP2014111127 A JP 2014111127A JP 2014159478 A5 JP2014159478 A5 JP 2014159478A5
- Authority
- JP
- Japan
- Prior art keywords
- biological system
- animal
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 29
- 241001465754 Metazoa Species 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 102000018511 hepcidin Human genes 0.000 claims 6
- 108060003558 hepcidin Proteins 0.000 claims 6
- 229940066919 hepcidin Drugs 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 206010022971 Iron Deficiencies Diseases 0.000 claims 4
- 206010065973 Iron Overload Diseases 0.000 claims 4
- 208000017667 Chronic Disease Diseases 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 2
- 108010054147 Hemoglobins Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000013060 biological fluid Substances 0.000 claims 2
- 238000005534 hematocrit Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014666 Endocarditis bacterial Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 201000000361 Hemochromatosis type 2 Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000036696 Microcytic anaemia Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000009361 bacterial endocarditis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 201000007119 infective endocarditis Diseases 0.000 claims 1
- 201000003453 lung abscess Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65347905P | 2005-02-16 | 2005-02-16 | |
| US60/653,479 | 2005-02-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011264338A Division JP5852426B2 (ja) | 2005-02-16 | 2011-12-02 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016183644A Division JP6250764B2 (ja) | 2005-02-16 | 2016-09-21 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014159478A JP2014159478A (ja) | 2014-09-04 |
| JP2014159478A5 true JP2014159478A5 (enExample) | 2014-11-13 |
| JP6073833B2 JP6073833B2 (ja) | 2017-02-01 |
Family
ID=36917026
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556264A Expired - Fee Related JP5063366B2 (ja) | 2005-02-16 | 2006-02-16 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2011264338A Expired - Fee Related JP5852426B2 (ja) | 2005-02-16 | 2011-12-02 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2014111127A Expired - Fee Related JP6073833B2 (ja) | 2005-02-16 | 2014-05-29 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2016183644A Expired - Fee Related JP6250764B2 (ja) | 2005-02-16 | 2016-09-21 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556264A Expired - Fee Related JP5063366B2 (ja) | 2005-02-16 | 2006-02-16 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2011264338A Expired - Fee Related JP5852426B2 (ja) | 2005-02-16 | 2011-12-02 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016183644A Expired - Fee Related JP6250764B2 (ja) | 2005-02-16 | 2016-09-21 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US7968091B2 (enExample) |
| EP (3) | EP2335719B1 (enExample) |
| JP (4) | JP5063366B2 (enExample) |
| CA (1) | CA2597925A1 (enExample) |
| ES (2) | ES2547866T3 (enExample) |
| HK (1) | HK1218875A1 (enExample) |
| WO (1) | WO2006088972A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4986370B2 (ja) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Ｒｇｍおよびそのモジュレーターの用途 |
| CA2448382C (en) * | 2001-05-25 | 2013-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin as a regulator of iron homeostasis |
| ES2551852T3 (es) | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US7968091B2 (en) * | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| US20070099245A1 (en) * | 2005-09-29 | 2007-05-03 | Boris Gorovits | Assays for neutralizing antibodies |
| EP1928905B1 (de) | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EA201692543A1 (ru) | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| EP2468291B1 (en) | 2006-12-18 | 2017-11-22 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| CA3039330C (en) | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| US8895002B2 (en) | 2007-04-09 | 2014-11-25 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2349332B1 (en) * | 2008-11-13 | 2019-10-23 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
| US20110293526A1 (en) * | 2008-11-20 | 2011-12-01 | University Of Southern California | Compositions and methods to modulate hair growth |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| KR20120118002A (ko) | 2009-12-08 | 2012-10-25 | 애보트 게엠베하 운트 콤파니 카게 | 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체 |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| EP2665752B1 (en) | 2011-01-19 | 2018-10-10 | Ferrumax Pharmaceuticals, Inc. | Compositions for regulating iron homeostasis and methods of using same |
| JP6336397B2 (ja) * | 2011-12-14 | 2018-06-06 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 鉄関連障害を診断および治療するための組成物および方法 |
| WO2013090635A2 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
| PE20190907A1 (es) | 2012-01-27 | 2019-06-26 | AbbVie Deutschland GmbH and Co KG | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
| JP6501362B2 (ja) * | 2012-11-01 | 2019-04-17 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | エリスロフェロンおよびｅｒｆｅポリペプチドならびに鉄代謝を調節する方法 |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| AR093620A1 (es) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| US20160051556A1 (en) * | 2013-03-21 | 2016-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression |
| EP3008465B1 (en) * | 2013-06-13 | 2019-08-07 | Biodesy, Inc. | Method of screening candidate biochemical entities targeting a target biochemical entity |
| AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| SMT202300166T1 (it) | 2014-12-03 | 2023-07-20 | Celgene Corp | Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| EP3237906B8 (en) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
| WO2016201077A1 (en) | 2015-06-12 | 2016-12-15 | Emory University | Growth and survival compositions for cells capable of producing antibodies and methods related thereto |
| EP3344660B1 (en) | 2015-08-31 | 2025-03-05 | National Research Council of Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| JP6810988B2 (ja) * | 2015-10-23 | 2021-01-13 | ヴィフォール （インターナショナル） アクチェンゲゼルシャフトＶｉｆｏｒ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） ＡＧ | 新規なフェロポーチン阻害剤 |
| CA3054135A1 (en) | 2016-02-22 | 2017-08-31 | Brigham Young University | Method and compositions for the treatment of anemia through the inhibition of furin |
| CN110381988A (zh) | 2016-06-15 | 2019-10-25 | 诺华股份有限公司 | 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法 |
| EP3589663A4 (en) | 2017-03-02 | 2020-10-21 | National Research Council of Canada | TGF-ß RECEPTOR ECTODOMAIN FUSION MOLECULES AND THEIR USES |
| US11125757B2 (en) | 2017-05-26 | 2021-09-21 | Emory University | Methods of culturing and characterizing antibody secreting cells |
| JP7504880B2 (ja) | 2018-10-26 | 2024-06-24 | ケロス セラピューティクス インコーポレイテッド | Ａｌｋ２阻害剤の結晶形 |
| KR20220088699A (ko) | 2019-09-27 | 2022-06-28 | 디스크 메디슨, 인크. | 골수섬유증 및 관련 상태의 치료 방법 |
| WO2021062171A1 (en) * | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | Methods for treating anemia of chronic disease |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098821A1 (en) * | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating lymphopenia |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| EP0414297B1 (en) | 1989-08-11 | 1996-10-16 | Gist-Brocades N.V. | Efficient production of mutant proteases |
| US5830847A (en) | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
| WO1994024314A1 (en) | 1993-04-19 | 1994-10-27 | Kauffman Stuart A | Random chemistry for the generation of new compounds |
| NZ276860A (en) | 1993-11-02 | 1997-09-22 | Affymax Tech Nv | Apparatus and its use for synthesising diverse molecular products on substrates |
| AU6267098A (en) | 1997-02-05 | 1998-08-25 | Regents Of The University Of California, The | Morphogenic proteins |
| EP1130094A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Primers for synthesizing full length cDNA clones and their use |
| CA2396719A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | 22 human secreted proteins |
| WO2002077006A1 (en) | 2001-03-23 | 2002-10-03 | Human Genome Sciences, Inc. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| US6800455B2 (en) | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
| CN1159063C (zh) * | 2000-06-21 | 2004-07-28 | 中国医学科学院血液学研究所 | 骨形态发生蛋白（bmp）作为治疗急性再生障碍性贫血药物的应用 |
| JP4986370B2 (ja) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Ｒｇｍおよびそのモジュレーターの用途 |
| CA2448382C (en) | 2001-05-25 | 2013-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin as a regulator of iron homeostasis |
| WO2003000461A1 (fr) | 2001-06-21 | 2003-01-03 | Meiyu-Giken Co., Ltd. | Procede de polissage de la surface d'extremite de connexion d'un connecteur a fibres optiques, structure optique et structure heterogene coaxiale de couches de materiau, et dispositif de polissage |
| US20040248249A1 (en) | 2001-07-05 | 2004-12-09 | Tran Uyen K | Secreted proteins |
| JP2003135075A (ja) | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| AU2003234136A1 (en) | 2002-04-18 | 2003-11-03 | The General Hospital Corporation | Drg11-responsive (dragon) gene family |
| WO2004003150A2 (en) | 2002-06-26 | 2004-01-08 | Yale University | Modulators and modulation of the interacton between rgm and neogenin |
| DE10230381A1 (de) | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen |
| GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| EP2006298A3 (en) | 2003-04-15 | 2009-04-22 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof |
| US20070184052A1 (en) * | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
| US20060063208A1 (en) | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
| US7968091B2 (en) * | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
-
2006
- 2006-02-16 US US11/884,509 patent/US7968091B2/en active Active
- 2006-02-16 EP EP10196139.9A patent/EP2335719B1/en active Active
- 2006-02-16 JP JP2007556264A patent/JP5063366B2/ja not_active Expired - Fee Related
- 2006-02-16 EP EP15173396.1A patent/EP2954903A1/en not_active Withdrawn
- 2006-02-16 CA CA002597925A patent/CA2597925A1/en not_active Abandoned
- 2006-02-16 ES ES10196139.9T patent/ES2547866T3/es active Active
- 2006-02-16 WO PCT/US2006/005367 patent/WO2006088972A2/en not_active Ceased
- 2006-02-16 ES ES06735151T patent/ES2392096T3/es active Active
- 2006-02-16 EP EP06735151A patent/EP1858541B1/en not_active Revoked
-
2011
- 2011-06-28 US US13/171,438 patent/US8293236B2/en not_active Expired - Fee Related
- 2011-12-02 JP JP2011264338A patent/JP5852426B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-28 US US13/407,502 patent/US8637023B2/en active Active
- 2012-10-18 US US13/654,623 patent/US8865168B2/en active Active
-
2014
- 2014-05-29 JP JP2014111127A patent/JP6073833B2/ja not_active Expired - Fee Related
- 2014-07-16 US US14/332,716 patent/US9556251B2/en not_active Expired - Fee Related
-
2016
- 2016-06-16 HK HK16106934.8A patent/HK1218875A1/en unknown
- 2016-09-21 JP JP2016183644A patent/JP6250764B2/ja not_active Expired - Fee Related
- 2016-12-12 US US15/375,491 patent/US20170183411A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014159478A5 (enExample) | ||
| JP2013172734A5 (enExample) | ||
| Zhao et al. | Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease | |
| HRP20210057T4 (hr) | Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije | |
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP2018532382A5 (enExample) | ||
| WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
| JP2018520648A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| BR112015023140A2 (pt) | proteínas de fusão il-22 fc, método para fabricar a proteína de fusão il-22 fc monomérica, composição, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar uma proteína de fusão il-22 fc, composições farmacêuticas e usos de uma composição farmacêutica | |
| HRP20201323T1 (hr) | Protutijela koja se specifično vežu na tl1a | |
| JP2015525217A5 (enExample) | ||
| RU2015142245A (ru) | Иммуномодифицирующие частицы для лечения воспаления | |
| PE20190845A1 (es) | Metodos para determinar resistencia a terapia de receptor de androgeno | |
| JP2021503485A5 (enExample) | ||
| JP2020520680A5 (enExample) | ||
| Criscitiello et al. | Deiminated proteins in extracellular vesicles and serum of llama (Lama glama)—Novel insights into camelid immunity | |
| WO2016100328A8 (en) | Novel tilapia virus and uses thereof | |
| Kumar De et al. | Alterations in oxidant/antioxidant balance, high-mobility group box 1 protein and acute phase response in cross-bred suckling piglets suffering from rotaviral enteritis | |
| JP2014504297A5 (enExample) | ||
| EA201890856A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение у животных | |
| MA32770B1 (fr) | Anticorps anti-peptides igf-1/e humain modifie | |
| Luka et al. | Seroprevalence of peste des petits ruminants antibodies in sheep and goats after vaccination in Karamoja, Uganda: implication on control | |
| WO2014153168A3 (en) | Porcine astrovirus sequences and uses thereof | |
| MX2018013177A (es) | Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. |